About us

Accelerating Discovery Through Innovation

Home / About Us

Our vision and values

Our vision is to accelerate discovery through innovation, empowering the latest scientific breakthroughs in basic research and transforming biotherapeutic development and manufacturing.

Bold

Caring

Creative

Sustainable

Our history

2018
First prototype debuts at Biophysical Society Meeting
Seminal paper in Science by Kukura lab, demonstrating mass photometry​
Refeyn spun out of the University of Oxford

2018

2019
OneMP launches​
Opening of first US office in Portland, Oregon​
20+ instruments installed ​
Seed+ Round Closes ($4.7m)​
R&D 100 Awards (Test Category)​
The Scientist Top 10 Innovations

2019

2020
Opening of US East Coast Office in Boston, Massachusetts​
Winner Best Technology Award (BioProcess UK Technology Showcase)​
Series A, led by Northpond Ventures ($24.4m)

2020

2021
Expansion of manufacturing facilities in Oxford, UK​
TwoMP launches​
100 instruments installed

 

2021

2022
SamuxMP and TwoMP Auto launch
Series B, led by Northpond Ventures ($70m)

2022

2023
SamuxMP Auto launches​
GMP compliance software launches for SamuxMP

2023

2024
KaritroMP launches
CIC opens in Waltham, Massachusetts with demo & service lab facilities​
500 papers feature mass photometry​​​​

2024

Refeyn by the numbers

Employees
0 +
Portfolio patents
0
Publications
0 +
Instruments in over 30 countries
~ 0

Our team

Gerry Mackay, CEO

Gerry Mackay, our CEO, brings more than thirty years of leadership experience in the Biopharmaceutical and Life Science industries to Refeyn. Most recently he was a member of the Sartorius Executive Board and Head of their Lab Division. Prior to Sartorius he was the CEO of BioOutsource , a contract research organisation that was sold to Sartorius in 2015. He has also worked in Executive positions and ran global operations for Millipore and Entegris  based in Europe, the US and Asia.

Jo Barette, Chief People Officer

Jo Barette, our Chief People Officer, joined Refeyn in January 2021 as the first HR hire. With a background as an HR Business Partner at Immunocore and Oxford Innovation, Jo brings a wealth of HR process experience to our team. She collaborates with the executive team to cultivate a collaborative, ambitious, and inclusive culture that aligns with our core values. Jo holds a B.Sc. in Biology from the University of Warwick and is a Member of the Chartered Institute of Personnel and Development.

Lewis Carney, Vice President of R&D

Lewis Carney is our Vice President of R&D and leads product development at Refeyn. His team turns concepts into new products and supports our existing portfolio.  Starting as a software engineer in medical software, computer vision, and data analysis, Lewis quickly moved into leadership roles. Joining Refeyn early in its history, Lewis has broad experience managing diverse teams across Software, Quality, and Engineering.

Paul Davies, CCO

Paul Davies, our Chief Commercial Officer, began his career at Unicam Instruments, a University of Cambridge spin-out, focusing on molecular spectroscopy. After moving to the US, he worked with several SMEs that were acquired by large multinationals, including Applied Systems (acquired by Mettler-Toledo) and SensIR (acquired by Smiths Detection). He later co-founded a company providing in-process spectroscopy tools to the pharmaceutical industry. Recently, Paul has held senior commercial roles at award-winning British companies, Malvern Instruments and Oxford Instruments.

Darko Stojkovic, COO

Darko Stojkovic is our Chief Operations Officer, bringing over 20 years of expertise in the medical devices and energy sectors. He has held key roles in engineering and manufacturing at renowned companies like Halma and Vestas. Darko has a proven track record of scaling businesses, managing technology transfers across Europe, America, and Asia, and enhancing the quality and efficiency of products, supply chains, and production processes. He holds a Doctorate in Engineering from Eindhoven University of Technology, the Netherlands.

Dan Cole, Chief Scientist and Co-Founder

Dan Cole, our Chief Scientist and co-founder, has been pivotal at Refeyn since its inception, driving instrument development and mass photometry research. He played a key role in developing mass photometry with the Kukura Group at the University of Oxford and now leads our Advanced Development and Innovation. Dan studied at the University of Warwick, focusing on ultrafast photo-induced dissociation of small molecules in the gas phase.

Fiona Coats, CMO

Fiona Coats, our Chief Marketing Officer, brings over 25 years in the Life Science tools industry, where she has held various roles in R&D, business development, product management, and marketing. She has successfully driven revenue growth and developed innovative go-to-market strategies at companies like Biosource International, Meso Scale Diagnostics, ThermoFisher Scientific, and Sartorius. Fiona holds a Ph.D. in Physiology and Pharmacology from Strathclyde University in Glasgow, UK.

Roshni Thakkar, General Counsel

Roshni Thakkar is our General Counsel. Having spent a number of years at Goodwin Procter, Roshni has acted as a trusted strategic advisor to various technology and life sciences’ focused investors and fast growth companies on venture capital investments at various stages of a company’s lifecycle, private equity investments, M&A transactions and general corporate lifecycle advisory matters. Roshni has worked closely with Refeyn since its inception.

Chris Hopegood Jones, Senior Finance Director

Chris Hopegood Jones is our Senior Finance Director. Chris trained at KPMG and worked for a fast-growing private equity backed business before joining Refeyn in February 2021. Chris directs and oversees the financial activities of Refeyn. He is responsible for financial strategy, planning, and reporting. Prior to training as an accountant, Chris earned a degree in Natural Sciences at the University of Cambridge, UK.

Gerry Mackay, CEO

Gerry Mackay, our CEO, brings more than thirty years of leadership experience in the Biopharmaceutical and Life Science industries to Refeyn. Most recently he was a member of the Sartorius Executive Board and Head of their Lab Division. Prior to Sartorius he was the CEO of BioOutsource , a contract research organisation that was sold to Sartorius in 2015. He has also worked in Executive positions and ran global operations for Millipore and Entegris  based in Europe, the US and Asia.

Heather Roxborough, Senior Partner at Oxford Science Enterprises

Heather Roxborough is a Senior Partner at Oxford Science Enterprises, leading the HealthTech team. With over 20 years of investment and company-building experience, she began her career at Unilever, creating healthcare businesses and spin-outs. Transitioning to venture capital, she spent 15 years with firms like J&J, leading Consumer HealthTech investments and partnering across EMEA. Before joining OSE, she was a Partner at Optum Ventures, establishing their Global HealthTech fund. Heather holds a PhD in Clinical Biochemistry from Queen’s University of Belfast.

Jonathan Flint

Jonathan Flint began his career designing satellites at Marconi, later acquired by BAE Systems. He held various technical and managerial roles, eventually becoming a managing director at both companies. In 2005, he became CEO of Oxford Instruments, leading it for 11 years through substantial growth. Currently, he is Chairman of the UK government Catapult, promoting growth in Compound Semiconductor applications. Jonathan has also served as Chairman of Marshall of Cambridge, Chairman of Quantic, and Senior Independent Non-executive Director for Cobham plc. He was President of the Institute of Physics (2019-2021) and is a Fellow of the IOP and the Royal Academy of Engineering. He is a trustee of the Oxford Trust and in 2012 received a CBE for services to Business and Science.

Andrea Jackson, Partner at Northpond Ventures

Andrea Jackson is a Partner at Northpond Ventures. She joined Northpond in 2020 after 12 years of operating and finance roles in small and large scientific and technology companies. Andrea’s work at Northpond focuses on portfolio management, new investments and leadership of the investment team. She serves on multiple Boards for the fund. Andrea received an MBA from Kellogg School of Management at Northwestern University and a B.A. in Economics with Honors from Washington University in St. Louis.

JP Mangeolle, Advisor

JP Mangeolle has more than 35 years of experience in life science and bioscience on a global scale. He served as President of Sciex (an operating company of Danaher Corp.), from 2014 to 2019. Previously, he was EVP for the Process Solutions Business Unit of Merck KGaA Millipore. Mangeolle spent more than 25 years with Millipore in different positions. Currently, he serves as an advisor to Asimov, Pillar Ventures, and as a board member of Refeyn  and Cube Biotech.

Philipp Kukura, Professor of Chemistry and Fellow of Exeter College

Philipp Kukura is a Professor of Chemistry and Fellow of Exeter College at the University of Oxford. He earned his MChem from Oxford (2002) and Ph.D. from UC Berkeley (2006). After postdoctoral work at ETH Zurich, he joined Oxford’s Chemistry Department, becoming a full Professor in 2016. His honors include the Klung-Wilhelmy Science Award (2018), Blavatnik Award for Young Scientists UK (2019), Emil Thomas Kaiser Award (2022), and Sackler International Prize in Biophysics (2023). He is the founder of Refeyn Ltd, that has enabled broad access to Mass Photometry. His current research focuses on using light microscopy and mass measurement to study biomolecular structures and interactions.

Justin Benesch, Professor of Biophysical Chemistry at the University of Oxford

Justin Benesch is Professor of Biophysical Chemistry at the University of Oxford, where his research group focusses on developing and applying quantitative mass measurement approaches for structural biology and biophysics. Justin is a co-founder of Refeyn, and assists in scientific strategy by convening and chairing the SAB. 

Volker Germaschewski, Senior Director of Therapeutic Platforms

Volker Germaschewskihas a molecular biology and protein science background, with most of his work being in antibody-based formats of biologics, but also has worked in vaccine technologies, as well as nucleic acid-based therapeutics. Having worked in both big pharma and biotechs, he is currently Senior Director of Therapeutic Platforms at LifeArc. 

Louise Duffy, CTO and CQO for Abzena

Louise Duffy is the Chief Technical Officer and Chief Quality Officer for Abzena, a CDMO/CRO with a focus on ADCs and complex-to-manufacture biologics. Louise has >30 years’ experience in the pharma and biotech industries (including J&J/Janssen and GSK), with a strong background in analytics, novel technologies across therapeutic modalities, and regulatory aspects. 

Philipp Kukura, Professor of Chemistry at the University of Oxford

Philipp Kukura is a Professor of Chemistry and Fellow of Exeter College at the University of Oxford. He earned his MChem from Oxford (2002) and Ph.D. from UC Berkeley (2006). After postdoctoral work at ETH Zurich, he joined Oxford’s Chemistry Department, becoming a full Professor in 2016. His honors include the Klung-Wilhelmy Science Award (2018), Blavatnik Award for Young Scientists UK (2019), Emil Thomas Kaiser Award (2022), and Sackler International Prize in Biophysics (2023). He is the founder of Refeyn Ltd, that has enabled broad access to Mass Photometry. His current research focuses on using light microscopy and mass measurement to study biomolecular structures and interactions.

Daniel (Danny) Galbraith , CSO of Solvias

Daniel (Danny) Galbraith is the Chief Scientific Officer of Solvias, an analytical testing (in-process and in-manufacturing) company with major focus on cell and gene therapy products and biologics. He has a background in virology and, previous to Solvias, worked for Merck Life Sciences leading product characterization and technology teams. 

Del Trezise, Vice Chair of the SAB

Del Trezise is vice chair of the SAB and brings a breadth of expertise across tools for the life sciences in his roles as technology scout for Sartorius, and Non Executive Director at Semarion, Axol Bioscience and ELRIG. Starting in pharma drug discovery, he has been developing workflows for cell and protein bioanalytics for >30 years. He co-founded and led the scientific team of Essen Bioscience (Incucyte), who were subsequently acquired by Sartorius. 

Want to join our team of experts?

 What’s it like being part of Team Refeyn? While we push the frontiers of biomolecular research, we also pride ourselves on creating a collaborative, diverse, and fun work environment that allows each individual to explore their potential to the fullest.

View job openings
Youtube Linkedin-in X-twitter

Visit the Refeynery: a mass photometry community forum

Refeyn Ltd.

Unit 9, Trade City, Sandy Ln W, Oxford OX4 6FF, United Kingdom

Phone: +44 1865 800175

Refeyn Headquarters
21 Hickory Drive, Ste. 200A,
Waltham MA 02451
USA

Phone: + 1 (971) 200 1370

© 2025 Refeyn Ltd. All Rights Reserved.